✦ LIBER ✦

5-31-15 A double-blind, randomized, placebo-controlled study of oral high-dose methylprednisolone in patients with attacks of multiple sclerosis

✍ Scribed by Sellebjerg, F.; Frederiksen, J.L.; Christiansen, M.; Nielsen, P.M.; Olesen, J.

Book ID: 122051069
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 170 KB
Volume: 150
Category: Article
ISSN: 0022-510X
DOI: 10.1016/S0022-510X(97)86473-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A double-blind controlled trial of high

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.

✍ Milligan, N. M. (author);Newcombe, R. (author);Compston, D. A.S. (author) 📂 Article 📅 1987 🏛 BMJ Publishing Group 🌐 English ⚖ 795 KB

A double-blind controlled trial of high

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.

✍ Milligan, N. M. (author);Newcombe, R. (author);Compston, D. A.S. (author) 📂 Article 📅 1987 🏛 BMJ Publishing Group 🌐 English ⚖ 795 KB

HAGIL (Hamburg Vigil Study): a randomize

HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis

✍ Moller, F.; Poettgen, J.; Broemel, F.; Neuhaus, A.; Daumer, M.; Heesen, C. 📂 Article 📅 2011 🏛 SAGE Publications 🌐 English ⚖ 180 KB

Oral laquinimod in patients with relapsi

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

✍ Comi, G.; Abramsky, O.; Arbizu, T.; Boyko, A.; Gold, R.; Havrdova, E.; Komoly, S 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 307 KB

Rituximab in patients with primary progr

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Efficacy and safety of oral fumarate in

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

✍ Ludwig Kappos; Ralf Gold; David H Miller; David G MacManus; Eva Havrdova; Volker 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 209 KB